Patents by Inventor Thorsten Knoechel

Thorsten Knoechel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolidone derivatives for use as MetAP-2 inhibitors
    Patent number: 8846694
    Abstract: Compounds of the formula (I), in which R, X, Y, Z, R3 and R4 have the meanings indicated in claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Grant
    Filed: May 13, 2009
    Date of Patent: September 30, 2014
    Assignee: Merck Patent GmbH
    Inventors: Timo Heinrich, Mireille Krier, Thorsten Knoechel, Alfred Jonczyk, Frank Zenke, Holger Enderle
  • Novel pyrrolidone derivatives for use as MetAP-2 inhibitors
    Publication number: 20110263561
    Abstract: Compounds of the formula (I), in which R, X, Y, Z, R3 and R4 have the meanings indicated in claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Application
    Filed: May 13, 2009
    Publication date: October 27, 2011
    Applicant: Merck Patent GmbH
    Inventors: Timo Heinrich, Mireille Krier, Thorsten Knoechel, Alfred Jonczyk, Frank Zenke, Holger Enderle
  • Crystalline EGFR - matuzumab complex and matuzumab mimetics obtained thereof
    Publication number: 20090175858
    Abstract: The invention relates to a crystal complex formed by the extracellular domain of EGF receptor (EGFR) and the Fab fragment of anti-EGFR antibody matuzumab (EMD 72000). Especially the invention relates to the identification of the epitope regions on said EGFR, which the antibody matuzumab recognizes as antigen an to which it specifically binds. The invention relates furthermore to protein, peptide and antibody structures which mimic the binding of matuzumab to its epitope region on EGFR, and may be used therefore, as EGFR antagonists with similar or improved properties as compared to matuzumab.
    Type: Application
    Filed: October 2, 2008
    Publication date: July 9, 2009
    Applicants: Merck Patent GmbH, The Trustees of the University of Pennsylvania
    Inventors: Kathryn M. Ferguson, Thorsten Knoechel, Judith Schmiedel